ID   SNU-2535
AC   CVCL_R756
DR   cancercelllines; CVCL_R756
DR   Cosmic; 1859888
DR   DepMap; ACH-002531
DR   KCLB; 02535
DR   Wikidata; Q54955156
RX   CelloPub=CLPUB00546;
RX   PubMed=23344087;
RX   PubMed=35852680;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Characteristics: Resistant to crizotinib (PubMed=23344087).
CC   Doubling time: 61 hours (CelloPub=CLPUB00546).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546; PubMed=35852680).
CC   Sequence variation: Mutation; HGNC; HGNC:427; ALK; Simple; p.Gly1269Ala (c.3806G>C); ClinVar=VCV000376132; Zygosity=Heterozygous (CelloPub=CLPUB00546; PubMed=35852680; DepMap=ACH-002531).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): KCLB=02535; CelloPub=CLPUB00546
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9,11
ST   D16S539: 9,11
ST   D18S51: 15
ST   D19S433: 10.2,14
ST   D21S11: 28,29
ST   D2S1338: 20,23
ST   D3S1358: 14,15 (CelloPub=CLPUB00546)
ST   D3S1358: 15 (KCLB=02535)
ST   D5S818: 10,12
ST   D7S820: 11
ST   D8S1179: 13,15
ST   FGA: 24,27
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-04-25; Version: 19
//
RX   CelloPub=CLPUB00546;
RA   Seo H.-Y.;
RT   "Establishment and characterization of 28 human lung cancer cell lines
RT   derived from pleural effusions.";
RL   Thesis MSc (2019); Seoul National University College of Medicine; Seoul; South Korea.
//
RX   PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0;
RA   Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L.,
RA   Chung D.H., Heo D.S.;
RT   "Heterogeneity of genetic changes associated with acquired crizotinib
RT   resistance in ALK-rearranged lung cancer.";
RL   J. Thorac. Oncol. 8:415-422(2013).
//
RX   PubMed=35852680; DOI=10.1007/s12094-022-02884-x;
RA   Xie B., Qiu Y., Zhou J., Du D., Ma H.-C., Ji J.-P., Zhu L.-Q.,
RA   Zhang W.-M.;
RT   "Establishment of an acquired lorlatinib-resistant cell line of
RT   non-small cell lung cancer and its mediated resistance mechanism.";
RL   Clin. Transl. Oncol. 24:2231-2240(2022).
//